Interspecies scaling of the monoclonal anti-EGF receptor ior EGF/r3 antibody disposition using allometric paradigm: is it really suitable?
The pharmacokinetic regularity of the murine monoclonal antibody ior EGF/r3 across mammals was studied using allometry. The allometric relationship between the volume of distribution and body weight (W) across mammalian species was characterized by the power equation V(d)=218.8 W(0.84) (r=0.92), and that for clearance by CL=2.96 W(0.76) (r=0.97, excluding the dog). The complex Dedrick plot of the ior EGF/r3 pharmacokinetic data produced a superimposable profile (r=0.73). However, a 4-fold variation was observed between the expected human ior EGF/r3 clearance and the cancer patients' values, using apolysichron time units. The patients showed clearance values that overreached the prediction, and the neoteny phenomena cannot explain such a difference. The pharmacokinetic data from cancer patients, rather than healthy volunteers, suggested any tumour-associated drug clearance process as a possible determinant of the mentioned underestimation. Finally, the results obtained in this study confirmed the potential use of allometric scaling to obtain more insight into the similarities and/or differences of the ior EGF/r3 disposition behaviour among mammals.